Midatech Pharma PLC Stock News

Midatech Pharma (NASDAQ: BDRX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program. According to a filing with the Securities and Exchange Commissio

Midatech Pharma PLC (AIM:MTPH) fell another 13% to 3p on Wednesday, having now slashed its market valuation by half in the past five days. A day earlier, Midatech announced the proposed acquisition of

Midatech Pharma PLC (AIM:MTPH) is in demand after a positive European approval for a key product. The biotechnology company said that the European Medicines Agency had granted orphan medicinal produc

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Midatech Pharma PLC's (NASDAQ: MTP) lead drug candidate MTX110 for the treatment of patients with recurrent glioblasto

Johnson & Johnson (JNJ) Janssen unit and U.K.-based Midatech Pharma are extending a research collaboration to include a second molecule.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc. (NYSE: ABBV ) and Alvotech announced a settlement agreement that gives Alvotech non-exclusive rights to market AVT01, a biosimilar to AbbVie''s Humira, in the U.S. The settlement gives Alvotech a license entry date into the U.S. of July 1, 2023. In February, the Food and Drug Administration accepted Alvotech''s biologic license application for ATV02, with the application including new data supporting interchangeability between ATV02 and Humira. AbbVie shares were adding 1.19% to $148.90 in premarket trading. NRx Pharma Founder & CEO Jonathan Javitt Retires NRx Pharmaceuticals, Inc. (NASDAQ: NRXP ) announced that Jonathan Javitt, the biopharma''s founder, has retired as chief executive officer, effective immediately. The board appointed Robert Besthof, Head of Operations and chief commercial officer, as Interim CEO.

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 180 points in the previous session. Investors are awaiting earnings results from Unite

Midatech Pharma extends R&D collaboration with Janssen

Nimba County District#7 Representative Roger Domah says there should be no extension given to ArcelorMittal to carry out operations in Nimba County because the company failed to live up to commitments made.

Midatech Pharma Plc - ADR (MTP) shares closed 1.8% lower than its previous 52 week low, giving the company a market cap of $23M. The stock is currently down 36.9% year-to-date, down 34.8% over the past 12 months, and down 99.1% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 72.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 451.0% The company's stock price performance over the past 12 months lags the peer average by 352.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The trading price of Midatech Pharma plc (NASDAQ:MTP) closed higher on Monday, December 13, closing at $1.41, 6.02% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced that its Investigational New Drug (IND) application for a Phase 1 study of MTX110, a panobinostat complex to be administered by convection enhanced delivery in patients with recurrent glioblastoma multiforme (rGBM), has been cleared by []

Midatech Pharma''s IND application for a Phase 1 study of MTX110 has been cleared by the US FDA

(PR-inside.com) Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective ABINGDON, OXFORDSHIRE / ACCESSWIRE / December 13, 2021 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that its Investigational New Drug (IND) application for a Phase 1 study of MTX110, a panobinostat complex to be administered by convection enhanced delivery in patients with recurrent glioblastoma multiforme (rGBM), has been cleared by the US FDA. Accordingly, Midatech has initiated preparations for a study start in the first half of 2022. Employing the Company''s MidaSolve ..

Credit Suisse AG purchased a new position in shares of Midatech Pharma plc (NASDAQ:MTP) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 38,716 shares of the companys stock, valued at approximately $81,000. A number of other large investors have also recently bought and []